FY2026 EPS Estimate for Voyager Therapeutics Cut by Analyst

Voyager Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • HC Wainwright cut its FY2026 EPS forecast for Voyager Therapeutics to a loss of $1.41 per share, from a loss of $1.32, while maintaining a Buy rating. Its estimate is less negative than the current consensus loss of $1.60 per share.
  • Voyager’s latest quarterly loss of $0.40 per share was slightly better than analysts’ $0.42 estimate, but revenue of $0.61 million fell well short of the $6.35 million consensus.
  • Analyst views are mixed: MarketBeat’s consensus rating is Moderate Buy with a $25 average price target, though two firms recently downgraded the stock. Shares opened at $1.63 after a reported 5.8% decline.
  • MarketBeat previews top five stocks to own in December.

Voyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report) - Equities researchers at HC Wainwright lowered their FY2026 earnings estimates for Voyager Therapeutics in a report issued on Friday, November 13th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings per share of ($1.41) for the year, down from their prior forecast of ($1.32). HC Wainwright currently has a "Buy" rating on the stock. The consensus estimate for Voyager Therapeutics' current full-year earnings is ($1.60) per share. HC Wainwright also issued estimates for Voyager Therapeutics' Q4 2026 earnings at ($0.15) EPS, Q1 2027 earnings at ($0.96) EPS, Q2 2027 earnings at ($1.17) EPS, Q3 2027 earnings at ($0.97) EPS, Q4 2027 earnings at ($0.55) EPS and FY2027 earnings at $0.12 EPS.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last released its earnings results on Thursday, November 5th. The company reported ($0.40) earnings per share for the quarter, topping analysts' consensus estimates of ($0.42) by $0.02. The firm had revenue of $0.61 million during the quarter, compared to the consensus estimate of $6.35 million. Voyager Therapeutics had a negative return on equity of 63.42% and a negative net margin of 416.32%.

Several other analysts have also weighed in on VYGR. Wall Street Zen lowered Voyager Therapeutics from a "sell" rating to a "strong sell" rating in a report on Saturday, November 7th. Weiss Ratings lowered Voyager Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a report on Friday. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Voyager Therapeutics presently has a consensus rating of "Moderate Buy" and an average price target of $25.00.

View Our Latest Analysis on VYGR

Voyager Therapeutics Trading Down 5.8%

Shares of VYGR stock opened at $1.63 on Tuesday. Voyager Therapeutics has a 1 year low of $1.58 and a 1 year high of $5.48. The business's fifty day moving average is $2.34 and its 200-day moving average is $3.34.

Hedge Funds Weigh In On Voyager Therapeutics

A number of hedge funds have recently modified their holdings of the stock. BlackRock Inc. acquired a new stake in Voyager Therapeutics during the 2nd quarter worth about $18,102,000. Renaissance Technologies LLC boosted its holdings in shares of Voyager Therapeutics by 95.0% in the first quarter. Renaissance Technologies LLC now owns 578,024 shares of the company's stock worth $2,231,000 after buying an additional 281,574 shares during the period. ADAR1 Capital Management LLC acquired a new position in shares of Voyager Therapeutics in the second quarter worth about $122,000. Hsbc Holdings PLC acquired a new position in shares of Voyager Therapeutics in the second quarter worth about $117,000. Finally, DLD Asset Management LP purchased a new position in shares of Voyager Therapeutics in the second quarter worth approximately $70,000. 48.03% of the stock is currently owned by institutional investors and hedge funds.

Voyager Therapeutics Company Profile

(Get Free Report)

Voyager Therapeutics is a biotechnology company developing genetic medicines for neurological diseases. Its work includes adeno-associated virus (AAV) gene therapies designed to deliver therapeutic genes to the nervous system. The company's TRACER platform is used to discover and engineer AAV capsids, including candidates intended to cross the blood-brain barrier. Voyager has researched treatments for neurodegenerative and other neurological disorders and has partnered with pharmaceutical companies to advance gene therapy programs.

Featured Articles

Earnings History and Estimates for Voyager Therapeutics (NASDAQ:VYGR)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Voyager Therapeutics Right Now?

Before you consider Voyager Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Voyager Therapeutics wasn't on the list.

While Voyager Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines